No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF

Stem Cells and Development
Yair GazittCharles Thomas

Abstract

Dendritic cells (DCs) are the most efficient antigen-presenting cells and play a role in immune reconstitution after autologous transplantation. Recent reports suggest that mobilization with granulocyte colony-stimulating factor (G-CSF) containing regimens polarizes DCs into pDC2, which could potentially result with increased Th2 response and decreased graft-versus-host disease (GVHD) in allogeneic transplantation and with decreased cytotoxic Th1 response and graft versus tumor effect, which in autologous transplantation could translate into increased relapse rate. Previously, we have shown that non-Hodgkin's lymphoma (NHL) patients receiving cyclophosphamide (CTX) plus granulocyte- macrophage (GM)-CSF, G-CSF or GM-CSF followed by G-CSF for stem cell collection, mobilize up to five-fold more mature CD80(+) DCs compared to CTX plus G-CSF mobilized patients. Here, we analyzed samples from the same study for the number of pDC1 and pDC2 subsets in blood and apheresis products obtained from these patients. Samples from 29 patients were collected. Patients mobilized with CTX plus G-CSF collected a mean of 1.2 +/- 0.4 x 10(6) pDC1/kg per day and 2.2 +/- 1 x 10(6) pDC2/kg per day, whereas patients mobilized with CTX plus GM-CSF collect...Continue Reading

References

Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W BensingerC Weaver
Mar 27, 2002·Nature Reviews. Immunology·Ken Shortman, Yong-Jun Liu
Aug 28, 2003·Cancer Immunology, Immunotherapy : CII·Malcolm S Mitchell
Jan 31, 2004·Seminars in Immunology·Kiyoshi Takeda, Shizuo Akira
Aug 21, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Luke R ShierStephen Couban

❮ Previous
Next ❯

Citations

Nov 19, 2009·Cancer Immunology, Immunotherapy : CII·Mohamed Labib Salem, David J Cole
Jun 19, 2007·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Chengzhong FanAbass Alavi
Nov 11, 2010·Journal of Translational Medicine·Giuseppina BonannoSergio Rutella
Mar 1, 2008·Biologics : Targets & Therapy·Martha Arellano, Sagar Lonial
Jul 16, 2009·Leukemia & Lymphoma·Julie M VoseJohn Dipersio
Jul 20, 2010·British Journal of Haematology·Morie A Gertz
Feb 11, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stefan Fruehauf, Guido Tricot
Jan 20, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Mohamed L SalemDavid J Cole

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.